• Sofen<sup>®</sup>



Mechanism of Action Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was
shown to inhibit multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET,
VEGFR-1, VEGFR-2, VEGFR-3 and PDGFR-ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis, and apoptosis. Sorafenib
inhibited tumor growth and angiogenesis of human hepatocellular carcinoma and renal cell carcinoma and several other human tumor xenografts in immunocompromised mice.

Sorafenib is a kinase inhibitor indicated for the treatment of
• Unresectable hepatocellular carcinoma
• Advanced renal cell carcinoma

Each commercial box contains 30 tablets in Alu-Alu blister pack


Related Products